The role of adjuvant chemotherapy for patients undergoing radical cystectomy for bladder cancer remains unresolved. Using a large international collaborative dataset this study evaluated the benefit of adjuvant chemotherapy among a unique group of patients who did not receive chemotherapy prior to surgery. The study utilizes a shared-frailty survival model to address the systematic bias associated with center based differences. In addition, we examined the association of adjuvant chemotherapy over a spectrum of disease risk by generating estimates of disease progression based on our multivariable regression model. Our observations indicate that selective use of adjuvant chemotherapy will provide benefit for approximately 20% of patients. Based on our findings, these patients can be identified based on the pathologic stage of their disease and the extent of nodal involvement. These findings have important implications in the practice of administration of adjuvant chemotherapy and in the design of adjuvant chemotherapy trials. 
Introduction
Urothelial carcinoma of the bladder (UCB) is the 4th most common cancer in men in the U.S (1) . Radical cystectomy (RC) and pelvic lymphadenectomy is the gold standard treatment for those patients with muscle-invasive or high-risk non-muscle-invasive disease (2) . This operation provides local cancer control and improves long-term survival (3, 4) . Unfortunately, however, disease recurrence is observed in 30-56% of patients undergoing surgery, most often the result of occult metastatic disease (4, 5) . The prognosis for patients with disease recurrence following cystectomy is poor. As a result, systemic perioperative chemotherapy has been explored as an adjunct to surgery in both neoadjuvant (preoperative) and adjuvant (postoperative) settings.
Cisplatin-based combination neoAC (neoAC) renders a 5-7% absolute survival benefit for patients undergoing cystectomy for UCB(6, 7). However, administration of neoAC for all patients undergoing radical cystectomy has not been widely adopted for several reasons: " (1) concerns that a substantial number of patients who do not benefit from neoAC will be treated unnecessarily; (2) in cases of inefficacy, chemotherapy delays time to surgery resulting in disease progression; and (3) the perception that selective administration of AC (AC), based on adverse pathologic characteristics, may be as effective as neoAC" (8) .
A number of randomized controlled trials have evaluated the benefit of AC. Some studies have demonstrated a treatment benefit, while others have not (9) (10) (11) (12) (13) (14) (15) . A recent meta-analysis of individual patient data from available trials reported a 25% relative reduction in the risk of death for those receiving AC compared to those undergoing surgery without AC (16) . In addition, a benefit of AC was also supported in the findings of a pooled analysis of phase III trials (8) .
Nevertheless, the conclusions drawn from these studies are limited due to individual trial method flaws and insufficient patients and events. As a result, the routine use of AC for patients undergoing radical cystectomy has not gained widespread acceptance. Moreover, these trials were carried out in highly (17, 18) . As a result, the efficacy of AC observed in the meta-analysis may not be as a great as the value in the off-protocol setting.
The purpose of this observational study is to determine the activity of AC in the off-protocol setting across an international cohort of patients undergoing radical cystectomy with lymphadectomy for bladder cancer. We hypothesize that AC is associated with a survival beneficial for a patients when used in routine clinical practice.
Methods

Patient selection and data collection
We retrospectively analyzed the clinical and demographic information of were at the investigator's discretion and based on patient tumor stage and overall health status. The AC regimen and number of cycles for each patient were not specified.
Pathologic evaluation
All surgical specimens were processed according to standard pathological procedures and all slides were reviewed by genitourinary pathologists according 
Data Analysis
The log-rank test statistic was used to compare estimated survival probabilities between groups. Univariable and multivariable Cox proportional hazards regression models addressed time to recurrence and time to cancerspecific mortality after radical cystectomy. Although lymph node density was significantly associated with cancer-specific mortality, it was excluded from the analysis in order to avoid model overfitting due to the strong direct correlation with pathologic nodal status. A shared-frailty survival model was used to account for heterogeneity and random effects based among the 11 centers. In all models, proportional hazards assumptions were systematically verified using the Grambsch-Therneau residual-based test. To determine if the effect of AC was modified by disease risk, estimates from the fitted multivariable Cox proportional hazards regression model were generated. Then patients were grouped into 5 equal numbered quintiles on the basis of their disease risk estimate. The association of AC with cancer-specific mortality across the 5 quintiles was then assessed using a univariable Cox proportional hazards regression model. and nodal status were significantly associated with survival (Table 2) .
We performed additional analyses to test the hypothesis that the effectiveness of AC is dependent on disease risk. Table 3 To illustrate key differences among the patients from the various quintiles, selected pathologic characteristics of patients within each quintile are shown in 
Discussion
We evaluated the effect of off-protocol AC on survival using a large international cohort of patients treated with radical cystectomy and lymphadenectomy for UCB. We found that the effect of AC on survival was contingent on the severity of the disease. Administration of AC resulted in a significant survival benefit in the patients at highest risk of death from disease but no definitive association between AC and survival was observed for a majority of patients.
The role of AC for patients undergoing radical cystectomy with lymphadenectomy remains unresolved. The p53 trial failed to show a survival benefit for AC in patients with high risk organ-confined disease but the study's power was limited by the lower than expected event rate and failure of some patients to receive the assigned therapy(19) Well designed adjuvant trials from
Italy and Spain failed to reach planned accrual and were consequently underpowered to detect a benefit for AC (11, 20) . Additional randomized clinical trials evaluating this approach have been widely criticized for inadequate sample size, poor reporting and/or method flaws (7, 8, 21) . A pooled analysis of randomized studies favored a benefit from AC, but with only 5 trials and 350 patients, the authors concluded that "larger studies are needed to identify the role of AC…" (8) . In addition, a well-designed meta-analysis of 491 individual patient A subset of patients with less advanced disease may derive therapeutic benefit from AC. Although pelvic nodal involvement and advanced pathologic stage are highly correlated with disease recurrence, some patients without these features will still experience relapse following surgery. Our findings do not support routine administration of AC to patients with pathologic T2, node negative disease, but we recognize that a benefit from AC for this subgroup of patients may require a larger number of patients and events. In our cohort, 26%
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research of patients with pathologic T2 disease and without nodal involvement experienced disease recurrence and 20% died from UCB. Clearly a subset of patients with pathologic T2 and node negative disease have occult metastasis at the time of surgery and may derive benefit from AC. To this end, enrollment in trials such as the p53 trial, which tested the utility of AC in patients with organconfined (pT1-T2) high-risk UCB based on p53 status, are strongly recommended as molecular stratification, pharmacogenetics, and/or improved imaging modalities will be necessary to tailor adjuvant therapy for these patients (22) .
We recognize the limitation of our study as a result of residual confounding not adjusted for in our analyses (23, 24) . Residual confounding is anticipated as many patients undergoing radical cystectomy have significant agerelated and/or smoking-related comorbidities which influence their ability to be selected for and/or tolerate AC and are casually related to the outcome (25) .
Unfortunately, patients' comorbidity status was not collected during data acquisition and it is expected that the absence of this information would systematically bias the results in favor of AC because healthier patients are more likely to receive AC.
We acknowledge additional limitations of this study. First, while the cooperation of multiple centers in this project increased the generalizability of our findings and the robustness of our estimates, these advantages may be at least partially offset by lack of control over data quality and homogeneity. For example, potentially meaningful characteristics such as pathologic T3a versus T3b, presence of hydronephrosis, or regimen and number of cycles of chemotherapy were not included. We did, however, consider differences among the 11 centers by using a shared-frailty survival model. This allowed for withinand between-center variability to diminish the influence of center-related differences on our estimates.
Second, our estimates for the effect of AC in the low-risk subgroup were underpowered due to the lack of events in this population and we acknowledge 
Conclusion
In this study, AC was associated with a significant improvement in survival among a large international cohort of patients treated in an off-protocol clinical setting. However, the benefit of AC was principally dependent on the individual's disease risk. Selective administration in patients at the highest risk for disease progression such as those with advanced pathologic stage and nodal involvement may optimize the therapeutic benefit of AC. 
